RG6913

Unknown / undisclosed

Mechanism not established

Automated registry profile: compiled from public clinical-trial and regulatory records; not yet individually analyst-verified.

—no registered trials

Evidence outlook

No clinical trials on ClinicalTrials.gov

No clinical trial of this drug is registered on ClinicalTrials.gov, so there is nothing to grade. Studies run outside that registry are not tracked here.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded.

No registered studies found. Not yet ingested, or none registered.

Competitive landscape

This drug's own stage for Diabetic Macular Edema: Stage not on record. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
RG6913: this drugStage not on recordUndisclosed—not yet gradedNo reviewed efficacy summary in this indication
Aflibercept (Eylea)ApprovedProtein / enzyme therapeuticVEGF-A, VEGF-A / VEGF-B / Placental Growth Factor (PlGF)not yet gradedNo reviewed efficacy summary in this indication
Aflibercept-Abzv (Enzeevu)ApprovedProtein / enzyme therapeuticVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Aflibercept-Ayyh (Pavblu)ApprovedProtein / enzyme therapeuticVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Aflibercept-Boav (Eydenzelt)ApprovedProtein / enzyme therapeuticVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Aflibercept-Jbvf (Yesafili)ApprovedProtein / enzyme therapeuticVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Aflibercept-Mrbb (Ahzantive)ApprovedProtein / enzyme therapeuticVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Aflibercept-Yszy (Opuviz)ApprovedProtein / enzyme therapeuticVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Brolucizumab-DbllApprovedAntibody fragmentVEGF-APartial signalNo reviewed efficacy summary in this indication
FaricimabApprovedMultispecific antibodyAngiopoietin-2 / VEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Ranibizumab (Lucentis)ApprovedAntibody fragmentVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Ranibizumab-Eqrn (Cimerli)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Ranibizumab-Hkdz (Ranluspec)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Ranibizumab-Leyk (Nufymco)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
RC28-EPhase 3Protein / enzyme therapeuticVEGF-A / FGF-2 (dual blockade)Partial signal
NCT05885503: Primary endpoint, mean BCVA change at week 52: non-inferior to aflibercept 2.0 mg (316 subjects) (2025-09-30).
Tabirafusp TedromerPhase 3Multispecific antibodyVEGF + IL-6not yet gradedNo reviewed efficacy summary in this indication
BI 1815368Phase 2——not yet gradedNo reviewed efficacy summary in this indication
MS-553Phase 1Small moleculeProtein kinase C-beta (PKC-beta)not yet gradedNo reviewed efficacy summary in this indication
MK-3000
—(overall)
Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
RG6209
—(overall)
Antibody fragment—not yet gradedNo reviewed efficacy summary in this indication
RG6697
—(overall)
Undisclosed—not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.